2. Academic Validation
  3. Effects of intraduodenal administration of tarazepide on pancreatic secretion and duodenal EMG in neonatal calves

Effects of intraduodenal administration of tarazepide on pancreatic secretion and duodenal EMG in neonatal calves

  • Regul Pept. 1998 Nov 30;78(1-3):113-23. doi: 10.1016/s0167-0115(98)00139-6.
R Zabielski 1,  V Leśniewska,  J Borlak,  P C Gregory,  P Kiela,  S G Pierzynowski,  W Barej
Affiliations

Affiliation

  • 1 Department of Animal Physiology, Warsaw Agricultural University, Poland. [email protected]
PMID: 9879754 DOI: 10.1016/s0167-0115(98)00139-6
Abstract

The influence of CCK-A receptor antagonism on pancreatic exocrine secretion and duodenal EMG, and the mechanism(s) involved in CCK-induced pancreatic secretion were studied in conscious calves. Seven 1-week-old calves were fitted with a pancreatic duct catheter, duodenal cannula and duodenal electrodes. Pancreatic exocrine secretion and duodenal EMG were studied following intraduodenal CCK-A receptor antagonist (Tarazepide), intravenous atropine, and intravenous or intraduodenal CCK-8 administrations. Tarazepide decreased duodenal electric activity, reduced interdigestive pancreatic secretion, especially protein; reduced cephalic and early postprandial (milk) induced secretion of bicarbonate and protein. Pancreatic protein secretion to intravenous CCK-8 was little affected by atropine, but was significantly reduced by Tarazepide+/-atropine; in contrast, protein secretion to intraduodenal CCK-8 was abolished by Tarazepide or atropine. We conclude that pre- and especially early postprandial pancreatic secretion are partly controlled via CCK-A (mainly mucosal) mediated mechanisms.

Figures
Products